Iovance Biotherapeutics Inc (IOVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Iovance Biotherapeutics Inc (IOVA) has a cash flow conversion efficiency ratio of -0.112x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-78.70 Million) by net assets ($702.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Iovance Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Iovance Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read IOVA current and long-term liabilities for a breakdown of total debt and financial obligations.
Iovance Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iovance Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Flowco Holdings Inc.
NYSE:FLOC
|
0.064x |
|
E2open Parent Holdings Inc
NYSE:ETWO
|
0.046x |
|
São Martinho S.A
SA:SMTO3
|
0.046x |
|
Sinodata Co Ltd
SHE:002657
|
0.002x |
|
alstria office REIT-AG
XETRA:AOX
|
-0.004x |
|
Fnac Darty SA
PA:FNAC
|
-0.386x |
|
Yotrio Group Co Ltd
SHE:002489
|
-0.224x |
|
Canfor Corporation
TO:CFP
|
0.018x |
Annual Cash Flow Conversion Efficiency for Iovance Biotherapeutics Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of Iovance Biotherapeutics Inc from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Iovance Biotherapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $710.40 Million | $-352.98 Million | -0.497x | +19.72% |
| 2023-12-31 | $584.61 Million | $-361.82 Million | -0.619x | -5.63% |
| 2022-12-31 | $499.64 Million | $-292.76 Million | -0.586x | -59.80% |
| 2021-12-31 | $621.66 Million | $-227.94 Million | -0.367x | -17.35% |
| 2020-12-31 | $656.50 Million | $-205.13 Million | -0.312x | +41.21% |
| 2019-12-31 | $298.97 Million | $-158.89 Million | -0.531x | -144.70% |
| 2018-12-31 | $466.19 Million | $-101.25 Million | -0.217x | +59.86% |
| 2017-12-31 | $145.48 Million | $-78.71 Million | -0.541x | -176.44% |
| 2016-12-31 | $166.92 Million | $-32.67 Million | -0.196x | -10.76% |
| 2015-12-31 | $104.02 Million | $-18.38 Million | -0.177x | +8.21% |
| 2014-12-31 | $44.85 Million | $-8.63 Million | -0.193x | +7.46% |
| 2013-12-31 | $17.60 Million | $-3.66 Million | -0.208x | -205.06% |
| 2012-12-31 | $-11.32 Million | $-2.24 Million | 0.198x | -59.11% |
| 2011-12-31 | $-12.78 Million | $-6.19 Million | 0.484x | +149.77% |
| 2010-12-31 | $638.09K | $-620.80K | -0.973x | -190.83% |
| 2009-12-31 | $-13.49K | $-14.45K | 1.071x | +104.27% |
| 2008-12-31 | $2.28K | $-57.30K | -25.089x | -- |
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic me… Read more